Transplant medicine recalled | Inquirer Business

Transplant medicine recalled

/ 10:14 AM May 11, 2014

AFP FILE PHOTO

MANILA, Philippines—A pharmaceutical firm has voluntarily recalled from the market a drug used in organ transplants and the treatment of aplastic anemia.

In an advisory, the Food and Drug Administration (FDA) said Sanofi-Aventis Philippines Inc. has initiated a voluntary recall of three batches of Rabbit Anti-Human Thymocyte Immunoglobulin, or Thymoglobuline.

Article continues after this advertisement

“Due to out of specification (OOS) findings on the product stability prior to the expiration date, specific batches of Rabbit Anti-Human Thymocyte Immunoglobulin (Thymoglobuline) 5mg/mL Powder for Solution for IV Infusion has been voluntarily recalled,” the FDA said.

FEATURED STORIES

Covered by the recall order are Thymoglobuline batches C1272H08 with expiry date of March 2014, C1282H20 and C1282H31, with expiry dates of May 2014.

The drug was manufactured by Genzyme Polyclonals S.A.S in France. Tina G. Santos

Article continues after this advertisement

RELATED STORIES

Article continues after this advertisement

 

Article continues after this advertisement

Filipinos make up biggest clientele of German fresh-cell therapy center

Mother’s medicine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Food and Drug Administration, Health Science, medicine, Pharmaceutical Firm

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.